Company Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.77 ^USD	-2.46%		+1.47%	+106.72%

May. 07	Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.

Number of employees: 25

Managers	Title	Age	Since
Jennifer Good FOU	Founder	59	11-02-28
Thomas Sciascia FOU	Founder	70	10-12-31
Lisa Delfini DFI	Director of Finance/CFO	54	21-08-08
Danine Summers CTO	Chief Tech/Sci/R&D Officer	-	21-08-08
David J. Clark CTO	Chief Tech/Sci/R&D Officer	59	22-11-13
Katie McManus IRC	Investor Relations Contact	-	-
Katherine Takaki LAW	General Counsel	-	-
Farrell Simon PRN	Corporate Officer/Principal	42	23-01-31
Christopher Galletta AUD	Comptroller/Controller/Auditor	-	21-04-11

Members of the board	Title	Age	Since
Anne VanLent BRD	Director/Board Member	76	18-10-09
James Cassella BRD	Director/Board Member	69	20-02-12
Jennifer Good FOU	Founder	59	11-02-28
Dominick Colangelo BRD	Director/Board Member	60	20-06-28
Ed Mathers Mathers BRD	Director/Board Member	64	17-06-30
Michael Heffernan BRD	Director/Board Member	59	17-01-31
David Meeker CHM	Chairman	69	17-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	70,435,093	69,546,959 ( 98.74 %)	0	98.74 %

Name	Equities	%	Valuation
NEA Management Co. LLC 16.49 %	11,370,376	16.49 %	29 M $
Frazier Life Sciences Management LP 10.70 %	7,381,090	10.70 %	19 M $
Rubric Capital Management LP 8.069 %	5,564,123	8.069 %	14 M $
Viking Global Investors LP 6.380 %	4,400,000	6.380 %	11 M $
Venrock Associates 4.963 %	3,422,675	4.963 %	9 M $
Opaleye Management, Inc. 3.836 %	2,645,000	3.836 %	7 M $
Vanguard Fiduciary Trust Co. 3.341 %	2,303,648	3.341 %	6 M $
BlackRock Advisors LLC 3.274 %	2,257,644	3.274 %	6 M $
Logos Global Management LP 3.190 %	2,200,000	3.190 %	6 M $
MPM BioImpact, Inc 1.945 %	1,340,960	1.945 %	3 M $

Trevi Therapeutics, Inc.

195 Church Street 14th floor

06510, New Haven

http://www.trevitherapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.77 USD

Average target price

7.4 USD

Spread / Average Target

+167.15%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TREVI THERAPEUTICS, INC.	+106.72%	195M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs